B. Riley Securities Maintains Buy on Veradermics, Raises Price Target to $204

Benzinga · 2d ago
B. Riley Securities analyst Mayank Mamtani maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $170 to $204.